NGS-based companion diagnostics

Fueling the future of precision medicine

Companion Diagnostics Development

The emergence of targeted therapies in oncology and other disciplines has increased the need for companion diagnostic tests. By providing detailed biomarker information through a multi-analyte approach, next-generation sequencing (NGS) is an ideal method for bringing precision medicine closer to everyday clinical practice.

In partnership with leading pharmaceutical companies and the oncology community, we are developing a universal oncology test system that aims to deliver a comprehensive set of the currently actionable and emerging biomarkers relevant to cancer drug development.

We are delivering companion diagnostic solutions to our pharmaceutical partners and clinical testing laboratories by building on the status of the Illumina MiSeqDx System as the first FDA-regulated and CE-IVD-marked NGS instrument for use in in vitro diagnostic procedures. In the future, we will continue to leverage advances in NGS technology to develop clinical tests that inform diagnosis and treatment.

We are committed to bringing the power of NGS to clinical diagnostics. The FDA-regulated and CE-IVD-marked MiSeqDx System offers an ideal platform to perform NGS-based assays. With its small benchtop footprint and easy-to-use interface, the MiSeqDx instrument delivers data output tailored to the needs of clinical labs. We offer two cystic fibrosis assays and a companion diagnostic for RAS mutational testing in colorectal cancer to determine eligibility for Vectibix® treatment.* Clinical labs can also use the MiSeqDx System and the TruSeq Custom Amplicon Kit Dx to develop their own diagnostic assays.

We intend to expand the menu offered on the MiSeqDx System through a development roadmap targeting applications in oncology.

*Vectibix is a registered trademark of Amgen, Inc.

 

We are engaged with leaders of the oncology pharmaceutical industry in an effort to bring companion diagnostic solutions to market. Since 2014, we have partnered with Amgen, Astra Zeneca, Merck Serono, and Sanofi to realize the value of precision oncology.

The Illumina Propel Certification Program is a collaborative service partnership. It is dedicated to ensuring you can obtain the high-quality data available for genetic analysis applications.

Illumina Propel certification provides a competitive advantage for service providers. It ensures that customers who use Illumina Propel services receive the industry-leading data quality and service they have come to expect from us.

Interested in receiving newsletters, case studies, and information on genomics in drug development? Enter your email address.
How Genomics is Shaping the Future of Oncology
How Genomics is Shaping the Future of Oncology

Read an interview with John Leite, VP of Marketing for Illumina’s Oncology business.

Read Interview
Aiming for a Standard Method in Clinical Research
Aiming for a Standard Method in Clinical Research

Almac Diagnostics is using the TruSight Tumor 170 assay for comprehensive high-quality genomic content in one streamlined workflow.

Read Article
Immunotherapy Research and NGS
Immunotherapy Research and NGS

An overview of exciting new fields of immunotherapy research, and how NGS helps to move them forward.

View PDF
Image
Removing Cancer's Veil: TruSight Tumor 170

A new enrichment-based cancer research assay interrogates both DNA and RNA, detecting small variants, gene amplifications, gene fusions, and splice variants.

View Video
Service Partners and Programs
Service Partners and Programs

The Propel Certification Program is designed to promote high data quality and best practices at fee-for-service labs powered by Illumina.

Learn More